Jason mccarthy maxim group
Web17 feb. 2024 · Maxim Group raised its price target for Artelo Biosciences (NASDAQ:ARTL) to $5 from $3, citing rising valuations across the cannabinoid and cannabis space, and as Artelo begins to map out its path forward as a cancer therapeutics company. The stock was changing hands at $2.70 at midday on Feb. 17. Analyst Jason McCarthy, Ph.D., writes … Web13 mai 2024 · Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s. Kilmer Lucas; ... writes analyst Jason McCarthy, Ph.D., adding that the PD data are a positive for ANVS401, which is an oral drug designed to mitigate neural inflammation and …
Jason mccarthy maxim group
Did you know?
Web4 mai 2024 · Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on May 4. The trial is evaluating motixafortide in combination with granulocyte colony-stimulating factor (G-CSF) in stem-cell … WebMaxim Group, LLC. Naz Rahman Jason McCarthy. Oppenheimer & Co. Francois Brisebois. Truist Securities. Srikripa Devarakonda Robyn Karnauskas. William Blair & Co. Tim Lugo. financial information. A comprehensive library of key 9 Meters reports. check out helpful investor resources View resources.
Web13 mai 2024 · Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s. … Web15 aug. 2024 · Senior Managing Director Biotechnology Jason McCarthy, Ph.D. is a Senior Managing Director covering the biotechnology industry at Maxim Group. Dr. McCarthy joined Maxim Group in July 2014. Prior to joining Maxim he received his doctoral degree in Biomedical Sciences at & Continue reading...
Web14 iun. 2024 · Maxim Group’s Jason McCarthy is bullish on cancer specialist Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) on the strength of its leukemia drug pipeline... This website uses cookies. We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about … WebJason McCarthy. Company: Maxim Group: Average Annual Return: 29.7%: Major Sector: healthcare: Action. Filter by Analyst Action. Stock Rating Date Rating Action Price Target …
Web23 mar. 2024 · In addition to the Company’s corporate presentation available on demand for registered attendees, N. Scott Fine, Chief Executive Officer and Lise Lund Kjems, MD, …
Web3 mar. 2024 · According to TipRanks.com, Maxim Group analyst Jason McCarthy is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of … t20 blast results 2022WebAcum 1 zi · ContraFect (CFRX – Research Report) received a Buy rating and a $3.00 price target from Maxim Group analyst Jason McCarthy today. The company’s shares … t20 blast rules 2022Web7 feb. 2024 · Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price target of … bravo\\u0027s hair salonWeb26 mai 2024 · The panel will include an interactive discussion moderated by Jason McCarthy, Ph.D., Maxim Group Senior Managing Director, Biotechnology. Among the topics to be discussed are how cell therapy can ... t20 aus vs pak schedulet20 blast televised gamesWeb30 mar. 2024 · Bionano Genomics (BNGO) 2nd Annual Maxim Group Conference March 30, 2024, 3:30 PM ET. Seeking Alpha - Go to Homepage. Trending. ... Michael Okunewitch — Maxim Group. Jason McCarthy. t20 iiiWebJason McCarthy, Ph.D. Maxim Group LLC. Enveric Biosciences is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Enveric Biosciences’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Enveric Biosciences or its management. t20 ii